Ken Griffin Maxcyte, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Maxcyte, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 600 shares of MXCT stock, worth $2,376. This represents 0.0% of its overall portfolio holdings.
Number of Shares
600
Previous 2,400
75.0%
Holding current value
$2,376
Previous $10,000
80.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding MXCT
# of Institutions
118Shares Held
65MCall Options Held
600Put Options Held
2.7K-
Black Rock Inc. New York, NY8.14MShares$32.2 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY7.62MShares$30.2 Million1.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$22.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.18MShares$20.5 Million0.01% of portfolio
-
Vitruvian Partners LLP5.04MShares$20 Million5.8% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $403M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...